Kardiale Resynchronisationstherapie (CRT-D) bei leichter Herzinsuffizienz

Abstract

Cardiac resynchronization therapy (CRT) is an important adjunct to medical therapy of heart failure. Necessary preconditions for a successful application of CRT are mechanical and electrical dyssynchrony of the left ventricle. Small clinical studies with a short follow-up time in patients with advanced systolic heart failure, structural heart disease, low LV ejection fraction (< 35 %) and a wide QRS complex (> 150 ms) demonstrated the beneficial effect of bi-ventricular pacing showing improvement of cardiac function and reduction of heart failure symptoms within a few weeks or months after initiation of CRT.

Large randomized trials (COMPANION and CARE-HF) in patients with advanced heart failure showed a decrease of overall mortality and less heart failure hospitalizations besides improvement of NYHA class. ICD backup in CRT devices proved to be important to reduce sudden arrhythmic death. Since the benefit of decreased overall mortality is limited in severe heart failure, three important trials (REVERSE, MADIT-CRT and RAFT) were launched in order to test the effect of CRT in patients with mild or asymptomatic heart failure (NYHA class I and II). The results of these trials with different study designs, follow-up time and primary endpoints demonstrated that significant „reverse remodeling“, reduction of overall mortality and decrease of heart failure hospitalization can be best achieved in patients with left bundle branch block (LBBB) configuration, a broad QRS complex ≥ 130 ms, sinus rhythm, female gender and non-ischemic cardiomyopathy.

Therefore, prevention of heart failure progression is easier to achieve at an early stage of heart failure by using bi-ventricular pacing with ICD backup. The long-term benefit of CRT in patients that fulfill the effectiveness criteria of CRT is more pronounced in patients with mild- instead of advanced heart failure.

Kernaussagen

• Nachdem bei schwerer Herzinsuffizienz (NYHA Klasse III/IV) gezeigt werden konnte, dass eine CRT die Herzinsuffizienzsymptomatik vermindert, die funktionelle Leistung steigern kann und einen günstigen, wenn auch nur mäßigen Effekt auf die Gesamtsterblichkeit, die kardiale Mortalität und die Hospitalisierung wegen Herzinsuffizienz hat, lag es nahe, den Effekt einer biventrikulären Stimulation auch bei einer leichteren Form der Herzinsuffizienz (NYHA Klasse II und I) und damit einer weniger fortgeschrittenen Insuffizienz zu untersuchen.

• In 3 großen, randomisierten Studien (REVERSE, MADIT-CRT und RAFT) konnte bewiesen werden, dass eine CRT bei leichter Herzinsuffizienz die Gesamtsterblichkeit senken, die Herzinsuffizienzereignisse vermindern und besonders ein „reverse remodeling“ der Ventrikeldilatation erreichen kann, das mit einer deutlichen Steigerung der linksventrikulären Auswurffraktion einhergeht.

• Dieser positive Effekt einer CRT bei leichter Herzinsuffizienz ist auf Patienten mit einer stark eingeschränkten LVEF ( ≤ 30 %) und einen LSB mit einer QRS-Breite im EKG ≥ 130 ms beschränkt – unabhängig vom Vorliegen einer KHK oder einer nicht ischämischen Kardiomyopathie.

• Voraussetzung für die günstige Wirkung der CRT auch bei leichter Herzinsuffizienz ist eine optimale medikamentöse Therapie der Insuffizienz.

• Selbst wenn eine CRT nur für etwa die Hälfte aller Patienten mit einer systolischen Herzinsuffizienz indiziert sein wird, erscheint sicher, dass die Verhinderung des Fortschreitens der Herzinsuffizienz in einem weniger fortgeschrittenen Stadium der myokardialen Schädigung wichtiger ist als die Implantation eines CRT-Systems in einem weit fortgeschrittenen Stadium mit voraussichtlich nur geringer und kurzzeitiger Milderung der Symptome und bescheidener Verbesserung der Prognose.

• Je früher ein unbehandelter, stets progredienter „Remodeling“-Prozess des Herzens durch CRT aufgehalten werden kann, desto größer wird die Möglichkeit sein, eine annähernd normale kardiale Pumpfunktion wiederherzustellen.

• Literatur

• 1 Lloyd-Jones DM, Larson MG, Leip EP et al. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation 2002; 106: 3068-3072
• 2 Fang J, Mensah GA, Croft JB et al. Heart failure related hospitalization in the US, 1979–2004. J Am Coll Cardiol 2008; 52: 428-434
• 3 Ross JS, Chen J, Lin Z et al. Recent national trends in readmission rates after heart failure hospitalization. Circ Heart Fail 2010; 3: 97-103
• 4 Hunt SA, Abraham WT, Chin MH et al. American College of Cardiology Foundation/American Heart Association 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol 2009; 53: 1-90
• 5 Jessup M, Abraham WT, Casey DE et al. 2009 focused up-date: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119: 1977-2016
• 6 Bax JJ, Bleeker GB, Marwick TH et al. Left ventricular dyssynchrony predicts response and prognosis after cardiac resynchronization therapy. J Am Coll Cardiol 2004; 44: 1834-1840
• 7 Piccini JP, Hernandez AF, Dai D et al. Use of cardiac resynchronization therapy in patients hospitalized with heart failure. Circulation 2008; 118: 926-933
• 8 McAlister FA, Ezekowitz J, Hooton N et al. Cardiac resynchronization therapy for patients with left ventricular systolic dysfunction: a systematic review. JAMA 2007; 297: 2502-2514
• 9 Bristow MR, Saxon LA, Böhmer J et al. Cardiacresynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004; 350: 2140-2150
• 10 Cleland JGF, Daubert JC, Erdmann E et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005; 352: 1539-1549
• 11 Cleland J, Freemantle N, Ghio S et al. Predicting the long-term effects of cardiac resynchronization therapy on mortality from baseline variables and the early response 20. J Am Coll Cardiol 2008; 52: 438-445
• 12 Lindenfeld JA, Feldman AM, Saxon L et al. Effects of cardiac resynchronization therapy with or without a defibrillator on survival and hospitalizations in patients with New York Heart Association. Circulation 2007; 115: 204-212
• 13 Vidal B, Delgado V, Mont L et al. Decreased likelihood of response to cardiac resynchronization in patients with severe heart failure. Eur J Heart Fail 2010; 12: 283-287
• 14 Linde C, Abraham WT, Gold MR et al. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J Am Coll Cardiol 2008; 52: 1834-1843
• 15 Gold MR, Linde C, Abraham WT et al. The impact of cardiac resynchronization therapy on the incidence of ventricular arrhythmias in mild heart failure. Heart Rhythm 2011; 8: 679-684
• 16 Daubert JC, Gold MR, Abraham WT et al. Prevention of disease progression by cardiac resynchronization therapy in patients with asymptomatic or mildly symptomatic left ventricular dysfunction. J Am Coll Cardiol 2009; 54: 1837-1846
• 17 Moss AJ, Hall WJ, Cannom DS et al. Cardiac resynchronization therapy for the prevention of heart failure events. N Engl J Med 2009; 361: 1329-1338
• 18 Zareba W, Klein HU, Cygankiewicz I et al. Effectiveness of cardiac resynchronization therapy by QRS morphology in the Multicenter Automatic Defibrillator Implantation Trial- Cardiac Resynchronization Therapy (MADIT-CRT. Circulation 2011; 123: 1061-1072
• 19 Solomon SD, Foster E, Bourgoun M et al. Effect of cardiac resynchronization therapy on reverse remodeling and relation to outcome: Multicenter Automatic Defibrillator Implantation Trial e Cardiac Resynchronization Therapy. Circulation 2010; 122: 985-992
• 20 Singh J, Klein HU, Huang D et al. Left ventricular lead position and clinical outcome in the MADIT-CRT trial. Circulation 2011; 123: 1159-1166
• 21 Ypenburg C, Van Bommel RJ, Borleffs CJ et al. Long-term prognosis after cardiac resynchronization therapy is related to the extent of left ventricular reverse remodeling at midterm follow-up. J Am Coll Cardiol 2009; 53: 483-490
• 22 Miyazaki C, Redfield MM, Powell BD et al. Dyssynchrony indices to predict response to cardiac resynchronization therapy. A comprehensive prospective single-center study. Circ Heart Fail 2010; 3: 565-573
• 23 Tang ASL, Wells GA, Talajic M et al. Cardiac resynchronization therapy for mild-to-moderate heart failure. N Engl J Med 2010; 363: 2385-2396
• 24 Epstein AE, Di Marco JP, Ellenbogen KA et al. ACC/AHA/HRS2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the ACC/AHA Task Force on Practice Guidelines developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation 2008; 117: 350-408
• 25 Lellouche N, De Diego C, Boyle NG et al. Relationship between mechanical and electrical remodeling in patients with cardiac resynchronization implanted defibrillators. EUROPACE 2011; 13: 1180-1187
• 26 Kashani A, Barold SS. Significance of QRS complex duration in patients with heart failure. J Am Coll Cardiol 2005; 46: 2183-2192
• 27 Beshai JF, Grimm RA, Nagüh SF et al. Cardiac-resynchronization therapy in heart failure with narrow QRS complexes. N Engl. J Med 2007; 357: 2461-2471
• 28 Dickstein K, Vardas PE, Auricchio A et al. 2010 focused update of ESC guidelines on device therapy in heart failure. An update of the 2008 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC guidelines for cardiac and resynchronization therapy. Eur Heart J 2010; 31: 2677-2687
• 29 Mc Murray JJV, Adamopoulos S, Anker S et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. The taskforce for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of cardiology. Eur Heart J 2012;